drugset / Trial / NCT04596527

18F-FMPP PET MPI in the Detection of Coronary Artery Disease

NCT04596527

Phase 0 Unknown 100 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

18F-FMPP is a novel PET myocardial perfusion imaging (MPI) tracer which targets to mitochondria complex I (MC-I). Preclinical animal studies have shown that its uptake is highly uniform and long in the heart and rather low in the liver. It may be a promising tracer for myocardial perfusion imaging. In addition, as a myocardial PET tracer, it is capable of quantifying absolute myocardial blood flow. Thus this prospective and open-label study is going to evaluate the diagnosis performance of 18F-FMPP PET MPI in suspected or known CAD patients who will be referred for invasive coronary angiography (ICA).

Timeline

Start
2020-09-15
Primary completion
2022-06
Completion
2022-09

Drugs

EvaluationDrugModalityDoseRoute
Subject XTR004 Diagnostic / imaging agent 92.5 mbq Intravenous
Subject XTR004 Diagnostic / imaging agent 222 mbq Intravenous